Insulin-like growth factor-binding protein-1 (IG-FBP
Insulin-like growth factors (IGF-I and IGF-II) 1 are associated with their specific binding proteins (IGFBPs) in extracellular fluids, and these binding proteins regulate IGF actions (1, 2) . The mechanisms responsible for IGFBP-induced changes are not well defined. Several post-translational modifications have been shown to alter the affinity of IGFBPs for IGFs, including phosphorylation (3, 4) , proteolysis (5, 6) , and polymerization (7, 8) . Dephosphorylation of human IGFBP-1 lowers its affinity for IGF-I by 6-fold (9) , and the addition of dephosphorylated IGFBP-1 to cells in culture has been shown to enhance the capacity of IGF-I to stimulate DNA synthesis (1, 10) . In contrast, phosphorylated IGFBP-1 inhibits IGF-I actions (2, 10) . Our laboratory has previously demonstrated that polymerized forms of IGFBP-1 were present in human amniotic fluid and were abundant in the chromatographic fractions of IGFBP-1 purified from amniotic fluid that had the capacity to potentiate IGF-I-stimulated thymidine incorporation into porcine smooth muscle cells (pSMC) (1, 7, 10) . In contrast, chromatographic fractions of purified IGFBP-1 that inhibited IGF-I actions had no detectable multimers (10) . The mechanism(s) accounting for the appearance of these multimers have not been determined. Tissue transglutaminase (transglutaminase type II) is a calcium-dependent enzyme that catalyzes the formation of isopeptide cross-links between glutamine and lysine residues and also can attach primary amines to peptide-bonded glutamines. The isopeptide cross-links are stable and resistant to proteolysis, thereby increasing resistance to chemical, enzymatic, or mechanical disruption. Tissue transglutaminase (Tg) activity is widely distributed in many tissues and organs, and it has been localized to the cytoplasm (11) , cell surface (12) , and extracellular matrix (13) . The ability of some proteins to polymerize and form covalently linked multimers is dependent upon this activity (14, 15) . Therefore, we speculated that IG-FBP-1 might be a substrate for tissue transglutaminase and that polymerization of IGFBP-1 might change its ability to modulate IGF-I actions in vitro. The current studies were undertaken to determine whether tissue transglutaminase could catalyze the polymerization of IGFBP-1, to identify the factors that enhanced or inhibited polymerization, and to analyze the effect of polymerization upon IGF-I actions.
Biomedical Inc. (Costa Mesa, CA). Tissue culture media, fetal calf serum, penicillin, streptomycin, and Geneticin (G418) were from Life Technologies, Inc. IGF-I was a gift from Genentech (South San Francisco, CA). Tissue transglutaminase and cystamine were purchased from Sigma. Native IGFBP-1 was obtained from media conditioned by CHO cells that had been transfected with an expression plasmid that contained the human IGFBP-1 cDNA (CHOBP1-D6) as previously described (3). Polyclonal rabbit antiserum for human IGFBP-1 was prepared as previously described (17) . A monoclonal antibody to tissue transglutaminase was purchased from NeoMarker (Fremont, CA). Polyvinylidene difluoride transfer membranes were obtained from Millipore Corp. (Bedford, MA).
Tissue Culture-Human fetal fibroblast (GM 10) cells were maintained in Eagle's minimum essential medium (EMEM) (Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% (v/v) calf serum, penicillin (100 units/ml), and streptomycin (100 g/ml). pSMC were cultured in Dulbecco's modified Eagle's medium (DMEM) (Life Technologies) supplemented with 10% fetal calf serum and antibiotics (100 units/ml penicillin and 100 g/ml streptomycin). The medium was changed on the third day after plating, and the cultures reached 80% confluency in another 3 days, at which time they were used for experiments. GM-10 cells were used between passages 8 and 16, and pSMC were used between passages 4 and 8.
Polymerization of IGFBP-1 with Tissue Transglutaminase-IG-FBP-1 (50 ng) was incubated with 0.5 microunits of pure tissue transglutaminase (purified from guinea pig liver) in reaction buffer containing 100 mM Tris-HCl, 20 mM dithiothreitol, 2.5 mM CaCl 2 , 10% (v/v) glycerol, pH 8.5, for the indicated times at 37°C (final assay volume 30 l). The reactions were terminated by the addition of 4ϫ Laemmli buffer containing 400 mM dithiothreitol and boiling for 10 min. The proteins were analyzed by 10% SDS-PAGE with immunoblotting for IGFBP-1 (7-9). The immune complexes were visualized using an alkaline phosphatase-conjugated anti-rabbit IgG and a phosphatase-dependent color development system as previously described (18) . For Western ligand blotting, the proteins were transferred to polyvinylidene difluoride membranes; probed in 4.0 ml of 10 mM Tris-HCl, 150 mM NaCl, 0.05% sodium azide, 1% bovine serum albumin (pH 7.4) containing 125 I-IGF-I (100,000 cpm/ml), specific activity 125 Ci/g; and then washed and visualized by autoradiography as described previously (19) . Densitometric quantification of the bands was performed by scanning the film and analyzing the band intensities using NIH Image.
Polymerization of IGFBP-1 in Human Fetal Fibroblast in Cultures-GM 10 cells were grown to 80% confluency on 24-well culture plates (Falcon Labware, division of Becton Dickinson, Franklin, NJ; catalog no. 3047). The cultures were rinsed once with serum-free EMEM and incubated for 5 h in 250 l of same medium. After the incubation, medium was replaced with serum-free EMEM containing 1 g/ml of either native or dephosphorylated IGFBP-1 and incubated for 20 -40 min at 37°C, and then 30 l of each sample was collected. The reactions were terminated by the addition of 4ϫ Laemmli buffer containing 400 mM dithiothreitol. The reaction products were analyzed by SDS-PAGE with Western immunoblotting for IGFBP-1.
Preparation of Membrane Extract from Human Fibroblasts-GM 10 cells were grown to confluency on 10-cm tissue culture dishes (Falcon; catalog no. 3003). The cultures were rinsed with serum-free EMEM and incubated overnight in the same medium in the presence or absence of IGF-I (30 ng/ml). The cells were scraped from the dishes with a cell scraper and washed three times with ice-cold Ca 2ϩ -and Mg
2ϩ
-free phosphate-buffered saline. The washed cells were sonicated in sonication buffer (20 mM Hepes, pH 7.4, 100 mM NaCl, 5 mM KCl, 0.3 mM Na 2 HPO4, 1 mM NaHCO 3 , 250 mM sucrose, 1 mM phenylmethanesulfonyl fluoride, 1 g/ml pepstatin, 1 g/ml leupeptin). The cell lysate was centrifuged at 16,000 ϫ g for 15 min, and the pellet was washed with the sonication buffer twice, solubilized in the same buffer containing 10 mM CHAPS, and centrifuged at 16,000 ϫ g for 15 min. The transglutaminase activity in the detergent-soluble membrane extracts was determined by adding 10.5 g of membrane protein to 30 l of the assay buffer described previously except that the tubes also contained 25 ng of IGFBP-1. To determine whether polymerization was being catalyzed by Tg, some tubes contained cystamine (20 mM), a specific inhibitor of Tg activity (20) .
Plasmid Construction for Expression of the IGFBP-1 Mutant-A fulllength human IGFBP-1 cDNA was cloned into the HindIII and XbaI sites of a mammalian expression vector pRcRSV (pRcRSV-hBP-1) that was prepared from the plasmid pRcCMV (Invitrogen, La Jolla, CA). The pRcRSV-hBP-1 contains a bacteriophage origin of replication that allows production of plasmid DNA in a single-stranded form suitable for site-directed mutagenesis. The mutant IGFBP-1 cDNA was generated using site-directed mutagenesis (21) . Single-stranded phagemid DNA was generated from pRcRSV-hBP-1, and the substitutions were introduced using synthetic oligonucleotide as a substrate for antisense DNA synthesis. The sequence of complementary oligonucleotide was 3Ј-CGT-GCAGAGGTGCCGCCTCCCCCGGCA-5Ј. This encoded conversions of Gln 66 to Ala and Gln 67 to Ala (designated pRcRSV-hBP-1Q66A/Q67A). The cDNA was sequenced, and the clones containing correct sequence were amplified. The plasmid DNA was purified using silica gel anion exchange resin chromatography (Qiagen, Chatsworth, MA).
Transfection of Chinese Hamster Ovary Cells-CHO-K1 cells were obtained from Lineberger Comprehensive Center Tissue Culture Facility (University of North Carolina). Cells were maintained in ␣-modified Eagle's minimum essential medium containing 10% fetal calf serum, penicillin, and streptomycin. CHO cells were transfected with the pRcRSV-hBP-1Q66A/Q67A using a standard calcium phosphate precipitation procedure (22) . The positive clones were selected with 800 g/ml of G418 and maintained in a long term culture in 400 g/ml G418.
Protein Purification-The Q66A/Q67A mutant IGFBP-1 was purified from conditioned medium of the pRcRSVhBP-1Q66A/Q67A-transfected CHO cells using procedures identical to those used to purify native IGFBP-1 as described previously (3) . Twenty micrograms of native IGFBP-1 was dephosphorylated by incubating it with 50 units of calf intestinal alkaline phosphatase at 37°C in 50 mM Tris-HCl, 0.1 mM EDTA (pH 8.5) for 16 h and repurified by reverse phase high pressure liquid chromatography. The purity of each form of IGFBP-1 was determined by SDS-PAGE with silver staining. Analysis of each form revealed a single monomeric band.
[ 35 S]Methionine Incorporation into pSMC-pSMC were grown to 80% confluency on 24-well culture plates. The cultures were rinsed once with serum-free DMEM and incubated overnight in the same media. After the incubation, media were replaced with 0.25 ml of methioninefree DMEM supplemented with 2 mM CaCl 2 for 4 h in the presence of 0.05 Ci/well [ 35 S]methionine (specific activity, 1, 206 Ci/mmol), IGF-I (0 or 50 ng/ml), and various concentrations of either native or mutant IGFBP-1 (0 -2,500 ng/ml). The plates were placed on ice, washed with ice-cold phosphate-buffered saline twice, and incubated with 10% trichloroacetic acid for 10 min. The trichloroacetic acid-precipitable radioactivity was solubilized in 1% SDS, 0.1 N NaOH and scintillation mixture (ScintiSafe TM Econo2; Fischer, Fair Lawn, NJ) and counted in a liquid scintillation counter (Beckman Instruments). Statistical comparisons were performed using a paired Student's t test.
RESULTS

IGFBP-1 Is a Substrate for Tissue
Transglutaminase-Following exposure to pure tissue Tg, IGFBP-1 formed covalent multimers that were stable during SDS-PAGE and were not altered with reducing agents (Fig. 1A) . Incubation with tissue transglutaminase was associated with a time-dependent increase in dimer and multimer formation (Fig. 1A) . Scanning densitometry showed that 57% of the total IGFBP-1 was present as polymerized forms after 5 h of incubation. When increasing concentrations of Tg were added, there was a progressive increase in dimer formation (Fig. 1B) .
Dephosphorylated IGFBP-1 Polymerizes More Readily Compared with Native IGFBP-1-To determine whether the phosphorylation status of IGFBP-1 affects its ability to polymerize, dephosphorylated IGFBP-1 (50 ng) was incubated with increasing concentrations of tissue Tg (0 -1.0 microunits/tube) for 30 min at 37°C, and the products of the reaction were analyzed by SDS-PAGE using reduced conditions (Fig. 2) . Dephosphorylated IGFBP-1 polymerized after exposure to 0.1 microunits of tissue Tg, whereas native IGFBP-1 required 0.4 microunits (Fig. 1B) or 0.5 microunits (Fig. 2) , were involved in the formation of Tg catalyzed polymerization, the Q66A/Q67A IGFBP-1 mutant was incubated with various concentrations of tissue Tg for 30 min at 37°C, and the prod-ucts of the reaction were analyzed by SDS-PAGE using reducing conditions. The Q66A/Q67A mutant IGFBP-1 required 1.0 microunit of Tg to polymerize (Fig. 3) , and only minimal amounts of dimer were detected. In contrast, the same concentration of native IGFBP-1 was polymerized to a much greater extent by 0.5 microunits of Tg. This reveals that substitution for Gln 66 -Gln 67 in IGFBP-1 inhibits transglutamination and that Gln 66 -Gln 67 is probably one of the cross-linking sites in IGFBP-1.
Enhancement of Polymerization of IGFBP-1 by IGF-I-Native IGFBP-1 was incubated with IGF-I at room temperature for 30 min. The IGF-I⅐IGFBP-1 complex was then incubated with 0.3 microunits of tissue Tg for 1 h at 37°C, and the reaction products were analyzed by SDS-PAGE using reducing conditions (Fig. 4) . The complexes containing IGF-I showed enhanced polymerization of IGFBP-1 by Tg compared with IGFBP-1 that was not exposed to IGF-I. Incubation with IGF-I and no Tg had no effect.
Polymerization of IGFBP-1 by Exposure to Fetal Fibroblast Cultures-Polymerization of IGFBP-1 had been observed previously in cell culture supernatants (7) . Since tissue Tg is widely distributed in many tissues and organs, we determined if exposure of IGFBP-1 to fibroblast cultures would allow polymerization. Native and dephosphorylated IGFBP-1 were polymerized within 20 min, when IGFBP-1 (1 g/ml) was added to GM 10 fetal fibroblast cultures (Fig. 5) . whether cellular membrane extracts could facilitate polymerization of IGFBP-1 and whether IGF-I altered the extent of polymerization, IGFBP-1 was incubated with fibroblast membrane extracts. Cell membrane extracts were prepared from cells that had been incubated for 14 h, and the samples were analyzed by SDS-PAGE under the reducing conditions (Fig.  6A) . Exposure of the cultures to IGF-I enhanced polymerization of both phosphorylated and dephosphorylated IGFBP-1 compared with membrane extracts from control cultures exposed only to serum-free medium. However, if IGF-I was added in vitro directly to the membrane extract, the extent of polymerization was much greater. When cystamine, a specific inhibitor of Tg, was coincubated with IGFBP-1 and the membrane extracts, no polymerization was observed (Fig. 6B) . Fig. 6C shows that these cellular membrane extracts contained equivalent concentrations of Tg.
Q66A/Q67A Mutant IGFBP-1 Inhibits IGF-I-stimulated Protein Synthesis on pSMC in Culture-pSMC were grown to 80% confluency in 24-well culture plates and the ability of IGF to stimulate [ 35 S]methionine incorporation into protein was determined. IGF-I stimulated the incorporation of [ 35 S]methionine into pSMC by 60% above the basal level. The addition of native IGFBP-1 at concentrations as high as 1,000 ng/ml reduced this response by 20%, although the decrease was not significant (p ϭ NS). Native IGFBP-1 (2,500 ng/ml) was required to obtain complete inhibition. In contrast, the addition of 1,000 ng/ml Q66A/Q67A mutant IGFBP-1 resulted in complete inhibition of protein synthesis that had been stimulated by IGF-I (p Ͻ 0.001) (Fig. 7) . Analysis of the forms of IGFBP-1 that were present in the media at the end of the incubation showed that the native IGFBP-1 polymerized, but the Q66A/ Q67A mutant IGFBP-1 was present only in the monomeric form. The scanning densitometric values of 1,000 ng/ml of mutant IGFBP-1 and 2500 ng/ml of native IGFBP-1 showed that approximately the same amount of monomeric IGFBP-1 was present. When the polyvinylidene difluoride membrane was probed with radiolabeled IGF-I, the intensity of the native IGFBP-1 monomeric band was reduced compared with Q66A/ Q76A mutant IGFBP-1 monomer. More importantly, the native IGFBP-1 polymeric form did not bind to radiolabeled IGF-I, and no band could be detected.
DISCUSSION
The current studies demonstrate that IGFBP-1 is a substrate for tissue Tg and that Gln 66 -Gln 67 is a one of the amine acceptor sites in IGFBP-1. This polymerization-resistant mutant form of IGFBP-1 potently inhibits IGF-I-stimulated protein synthesis into pSMC. In contrast, when polymerizable native IGFBP-1 was added, much higher concentrations were required to inhibit IGF-I action. The polymerization of IGFBP-1 by tissue Tg was also shown to be altered by the phosphorylation state of IGFBP-1 and by the presence of IGF-I in the incubation buffer.
Numerous proteins have been demonstrated as substrates for Tg; however, a general consensus recognition sequence for transglutaminase has not been determined. Two directly adjacent glutamine residues have frequently been identified as amine-accepting sites. The ␥-chain of fibrinogen (23) and fibronectin (24) , which contain adjacent glutaminase residues, are substrates for factor XIIIa. Plasminogen activator inhibitor-2 (25), ␤ A3-crystallin (26) , and BM-40 (osteonectin) (27) are substrates for tissue Tg, and they have two directly adjacent glutamine residues that have been identified as amine acceptor sites. In addition, positively or negatively charged amino acid residues are often found near amine acceptor sites in the sequence of these proteins. Analysis of the sequences following Gln 66 -Gln 67 in IGFBP-1 showed that both positively (Glu 65 ) and negatively (His 70 ) charged residues are present (Fig. 8 ). The positions of charged residues in several other substrates for tissue Tg are shown for comparison. Because of these similarities, we speculated that the adjacent glutamine residues in IGFBP-1 (Gln 66 -Gln 67 ) could be amine acceptor sites. The Q66A/Q67A mutant form of IGFBP-1 that was generated was resistant to polymerization by pure tissue Tg and following exposure to cell cultures that contained tissue Tg in their membrane extracts. These findings strongly support the conclusion that tissue Tg is using these residues as amine acceptor sites for cross-linking in IGFBP-1.
IGFBP-1, -2, -3, and -5 have been shown to stimulate or inhibit IGF-I actions in vitro (28) . Most studies have shown that excess concentrations of IGFBP-1 inhibit the IGF-I actions in vitro, particularly if high concentrations of IGFBP-1 are added using serum-free conditions (2, 10, 29 -31) . When platelet-poor plasma is added with IGF-I and dephosphorylated IGFBP-1, IGFBP-1 has been shown to potentiate the IGF-Istimulated DNA synthesis in cultured fibroblasts and pSMC (1) . The phosphorylation state of IGFBP-1 was also shown to be an important determinant of this response, and dephosphorylated IGFBP-1 was much more effective than phosphorylated IGFBP-1 (1, 9, 32) . Analysis of the cell culture supernatants at the end of these incubations showed that the added IGFBP-1 had polymerized. Therefore, the current studies were undertaken to determine whether IGFBP-1 polymerized as a result of exposure to transglutaminase, if its phosphorylation status of IGF-I affected its capacity to polymerize, and if polymerization would be associated with a decrease in the ability to inhibit IGF-I-stimulated protein synthesis.
IGFBP-1 is a phosphoprotein that undergoes serine phosphorylation (9) . Several phosphoisoforms of IGFBP-1 have been detected in serum, and the presence of highly phosphorylated forms of IGFBP-1 in physiologic fluids has been associated with conditions in which the target tissue actions of IGF-I are being inhibited (32, 33) . Separation of phosphoisoforms of IGFBP-1 by anion exchange chromatography has shown that chromatographic fractions that contain phosphorylated forms inhibit IGF-I actions, whereas those that are enriched in nonphosphorylated forms did not inhibit IGF-I actions (9, 10, 28) . In this study, dephosphorylated IGFBP-1 polymerized to a much greater extent compared with phosphorylated IGFBP-1. Since the ability of IGFBP-1 to polymerize has also been shown to be related to the loss of its capacity to inhibit IGF-I actions, these results suggest that this may be one mechanism by which phosphorylation of IGFBP-1 may enhance its capacity to inhibit IGF-I actions.
The results of several studies have shown that the loss of the ability of IGFBP-1, IGFBP-3, and IGFBP-5 to inhibit IGF-I actions is associated with a reduction in their affinities for IGF-I (9, 34 -38). IGFBPs have high affinity for IGF-I, and their affinities are greater than that of the type-I IGF receptor. Therefore, factors such as dephosphorylation (3) or adherence to cell surfaces (18) , which lower their affinity for IGF-I, will reduce their capacity to inhibit IGF-I actions, and in some cases this has been associated with stimulation of IGF-I actions (1). Our results showed that the multimeric form of IGFBP-1 (Fig.  7 ) that occurred following transglutamination had very low binding capacity for IGF-I and that polymerization was associated with a loss of IGFBP-1's inhibitory effect. Immunoblotting analysis at the end of incubation revealed that the concentration of monomeric IGFBP-1 correlated with the extent of inhibition of IGF-I action. This result suggests that polymerization is also an important mechanism by which the inhibitory effect of IGFBP-1 is attenuated.
The N-terminal domain of IGFBP-3 and -5 contain a binding site for IGF-I (39). In IGFBP-5, the IGF-I binding site is contained within amino acids 49 -74, and in IGFBP-3 it is between residues 50 and 75. , and Leu 70 are homologous, suggesting that this is also an important site in IGFBP-1 for IGF-I binding. Our results demonstrate that following transglutamination, which occurs through Gln 66 -Gln 67 , the affinity of IGFBP-1 is markedly reduced. This suggests that cross-linking through these sites alters the conformation of the adjacent IGF-I binding site such that IGF-I has reduced access.
Our results also show that IGF-I stimulates the polymerization of IGFBP-1 by pure tissue Tg and by the Tg that was contained in fibroblast membrane extracts. The effect is direct and does not require the presence of some other component. Since IGF-I is probably binding to the region of IGFBP-1 that contains the amine acceptor sites, its presence may induce a conformational change in IGFBP-1 that stabilizes the conformation of the multimeric forms and facilitates cross-linking by tissue Tg.
Recently, tissue Tg has been shown to associate with ␤ 1 and ␤ 3 integrins, and it has been estimated that 5-40% of ␤ 1 integrins on the cell surface are complexed with tissue transglutaminase. Tissue Tg on the cell surface has been shown to FIG. 8 . Comparison of amino acid sequences flanking the two adjacent glutamine residues that have been identified as amine acceptor sites. Two adjacent glutamine residues (amine acceptor site) are underlined, and charged residues are in boldface type for IGFBP-1 and other proteins that have been noted to undergo transglutamination.
increase cell adhesion and spreading on fibronectin (40) . IG-FBP-1 has been shown to bind to the ␣ 5 ␤ 1 integrin and stimulate cell migration independently of IGF-I (41). Ligand occupancy of ␣ 5 ␤ 1 by IGFBP-1 has been shown to induce focal adhesion kinase and PI 3-kinase. Therefore, IGFBP-1 could form an IGFBP-1-tissue Tg complex with the ␤ 1 integrin, and transglutamination of IGFBP-1 could potentially modulate the ␣ 5 ␤ 1 integrin-linked signaling. Elucidation of the interaction between IGFBP-1 and tissue Tg will be a great help in further analysis of the biological significance of multiple IGFBP-1/ IGF-I interactions that occur in vivo.
